Nanbacine

Nanbacine is a biotechnology company focused on developing a new class of anti-infective agents to combat the global threat of multidrug-resistant (MDR) bacteria. The company's proprietary platform utilizes unique molecular structures designed to disrupt bacterial membranes and cell walls through mechanisms that are difficult for pathogens to develop resistance against. Nanbacine's lead candidates are currently in pre-clinical development, targeting high-priority pathogens including ESKAPE organisms. By focusing on novel modes of action, the company aims to provide effective treatments for life-threatening infections where current antibiotics fail.